


Product Details

Product name:	Anti-IL-13 & IL-4 (Romilkimab Biosimilar)	SKU:	BIO0975SM
Target Name:	IL-13 & IL-4	Size:	100ug/ 1mg/ 5mg
Target Uniprot:	P35225 & P05112	Concentration:	Lyophilized
Clone#:	Romilkimab (Bispecific)	Isotype:	DVD-Ig
Reactivity:	Human	Calculated M.W.:	198.12 kDa
Application:	ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<0.001 EU/ug
Formulation:	100 mM Pro-Ac 20mM Arg pH 5.0	Conjugation:	None
Storage:	-20°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.	Expression System:	CHO
Reconstitution:	Dissolve with sterile ddH ₂ O	Purification:	Protein A


Data

Purity: SDS-PAGE




Anti-IL-13 & IL-4 Reference Antibody (romilkimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC




The purity of Anti-IL-13 & IL-4 Reference Antibody (romilkimab) is 97.45%, determined by SEC-HPLC.

ELISA



Romilkimab bound to IL-4 protein, and then rebounded to secondary antibodies (Anti-Human- κ + λ -HRP), and read OD450. As shown in fig, Romilkimab bound to Human IL-4-Fc, and the EC₅₀ was 0.040 nM.

ELISA



Romilkimab bound to IL-3 protein, and then rebounded to secondary antibodies (Anti-6*his-HRP), and read OD450. As shown in fig, Romilkimab bound to Human IL-3-His, and the EC₅₀ was 0.088 nM.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.